Comparison of clot lysis activity and biochemical properties of originator tenecteplase (Metalyse®) with those of an alleged biosimilar

Frontiers in Pharmacology

Volumn 5 FEB, Issue , 2014, Pages

  Kliche, Werner ^a   Krech, Ingo ^a   Michel, Martin C ^a,b   Sangole, Nishant V ^c   Sathaye, Sadhana ^d  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c Michigan Engineers Pvt Ltd   (India)

^d INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

Author keywords

Biosimilar; Clot lysis; Glycosylation; Impurity; Tenecteplase

Indexed keywords

BIOSIMILAR AGENT; CELL PROTEIN; ELAXIM; SIALIC ACID; TENECTEPLASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BIOCHEMISTRY; BLOOD CLOT LYSIS; CHO CELL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DETERMINATION; DRUG PURITY; DRUG QUALITY; FIBRINOLYSIS; GLYCOSYLATION; IN VITRO STUDY; NONHUMAN; PRACTICE GUIDELINE; QUALITY CONTROL;

EID: 84895525056     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2014.00007     Document Type: Article

References (19)

1. Davydov, L., and Cheng, J. W. M. (2001). Tenecteplase: a review. Clin. Ther. 23, 982-997. doi: 10.1016/S0149-2918(01)80086-2.
2. Iyengar, S. S., Nair, T., Hiremath, J. S., Jadhav, U., Katyal, V. K., Kumbla, D., et al. (2011). Efficacy and safety of tenecteplase in 6000 patients with ST-elevation myocardial infarction from the Elaxim Indian Registry. Indian Heart J. 63, 104-107.
3. Iyengar, S. S., Nair, T., Hiremath, J. S., Jadhav, U., Katyal, V. K., Kumbla, D., et al. (2013). Pharmacologic reperfusion therapy with indigenous tenecteplase in 15,222 patients with ST elevation myocardial infarction-the Indian registry. Indian Heart J. 65, 436-441. doi: 10.1016/j.ihj.2013.06.010.
4. Jiang, H., Wu, S.-L., Karger, B. L., and Hancock, W. S. (2010). Characterization of the glycosylation occupancy and the active site in the follow-on protein therapeutic: TNK-tissue plasminogen acivator. Anal. Chem. 82, 6154-6162. doi: 10.1021/ac100956x.
5. Kuhlmann, M., and Marre, M. (2010). Lessons learned from biosimilar epoetins and insulins. Br. J. Diab. Vasc. Dis. 10, 90-97. doi: 10.1177/1474651409355454.
6. Kunadian, V., and Gibson, M. (2012). Thrombolytics and myocardial infarction. Cardiovasc. Ther. 30, e81-e88. doi: 10.1111/j.1755-5922.2010.00239.x.
7. Llevadot, J., Giugliano, R. P., and Antman, E. M. (2001). Bolus fibrinolytic therapy in acute myocardial infarction. J. Am. Med. Assoc. 286, 442-449. doi: 10.1001/jama.286.4.442.
8. Melandri, G., Ganarelli, F., Calabrese, D., Semprini, F., Nanni, S., and Branzi, A. (2009). Review of tenecteplase (TNKase) in the treatment of acute myocaridal infarction. Vasc. Health Risk Manag. 5, 249-256. doi: 10.2147/VHRM.S3848.
9. Mohanan, P. P., Mathew, R., Harikrishnan, S., Krishnan, M. N., Zachariah, G., Joseph, J., et al. (2013). Presentation, management, and outcomes of 27 748 acute coronary syndrome admissions in Kerala, India: results from the Kerala ACS Registry. Eur. Heart J. 34, 121-129. doi: 10.1093/eurheartj/ehs219.
10. Neuhoff, V., Stamm, R., and Eibl, H. (1985). Clear background and highly sensitive protein staining with Coomassie Blue dyes in polyacrylamide gels: a systematic analysis. Electrophoresis 6, 427-448. doi: 10.1002/elps.1150060905.
11. Oakley, B. R., Kirsch, D. R., and Morris, N. R. (1980). A simplified ultrasensitive silver stain for detecting proteins in polyacrylamide gels. Anal. Biochem. 105, 361-363. doi: 10.1016/0003-2697(80)90470-4.
12. Parekh, R. B., Dwek, R. A., Rudd, P. M., Thomas, J. R., Rademacher, T. W., Warren, T., et al. (1989a). N-Glycosylation and in vitro enzymatic activity of human recombinant tissue plasminogen activator expressed in Chinese hamser ovary cells and a murine cell line. Biochemistry 28, 7670-7679. doi: 10.1021/bi00445a023.
13. Parekh, R. B., Dwek, R. A., Thomas, J. R., Opdenakker, G., and Rademacher, T. W. (1989b). Cell-type-specific and site-specific N-glycosylation of type I and type II human tissue plasminogen activator. Biochemistry 28, 7644-7662. doi: 10.1021/bi00445a021.
14. Pohl, G., Källström, M., Bergsdorf, N., Wallen, P., and Jörnvall, H. (1984). Tissue plasminogen activator: peptide analyses confirm an indirectly derived amino acid sequence, identify the active site serine residue, establish glycosylation sites, and localize variant differences. Biochemistry 23, 3701-3707. doi: 10.1021/bi00311a020.
15. Schellekens, H. (2009). Biosimilar therapeutics-what do we need to consider? NDT Plus 2(Suppl. 1), i27-i36. doi: 10.1093/ndtplus/sfn177.
16. Steg, P. G., James, S. K., Atar, D., Badano, L. P., Blömstrom-Lundqvist, C., Borger, M. A., et al. (2012). ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur. Heart J. 33, 2569-2619. doi: 10.1093/eurheartj/ehs215.
17. Stewart, R. J., Fredenburgh, J. C., Leslie, B. A., Keyt, B. A., Rischke, J. A., and Weitz, J. L. (2000). Identification of the mechanism responsible for the increased fibrin specificity of TNK-tissue plasminogen activator relative to tissue plasminogen activator. J. Biol. Chem. 275, 10112-10120. doi: 10.1074/jbc.275.14.10112.
18. Stief, T. W., Martin, E., Jimenez, J., Digon, J., and Rodriguez, J. M. (1991). Effect of oxidants on proteases of the fibrinolytic system: possible role for methionine residues in the interaction between tissue type plasminog activator and fibrin. Thromb. Res. 61, 191-200. doi: 10.1016/0049-3848(91)90095-E.
19. Tanswell, P., Modi, N., Combs, D., and Danays, T. (2002). Pharmacokinetics and pharmacodynamics of tenecteplase in fibrinolytic therapy of acute myocardial infarction. Clin. Pharmacokinet. 41, 1229-1245. doi: 10.2165/00003088-200241150-00001.